Cymbalta recalled over nitrosamine cancer-risk contamination
Nearly 370,000 bottles of duloxetine (Cymbalta) are being recalled after the FDA flagged levels of the nitrosamine contaminant N-nitroso-duloxetine that exceed safety limits, potentially increasing long-term cancer risk. The Class II recall covers 30 mg and 60 mg bottles with specific lot codes; no adverse effects have been reported yet. Patients should consult their healthcare provider before stopping the medication abruptly, as withdrawal can occur.